SuperworthAlnylam Pharmaceuticals shares outstanding ALNY
Diluted shares outstanding, averaged over each quarter, from 2009.
- Latest quarter, to Jun 30, 2026
- 138.3M
- On a year earlier
- +5.9%
- more shares
Alnylam Pharmaceuticals had 138.3M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 5.9% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 136.3M | +6% |
| FY2024 | 129.1M | +3% |
| FY2023 | 125.6M | +2% |
| FY2022 | 123.3M | +3% |
| FY2021 | 119.8M | +3% |
| FY2020 | 116.3M | +4% |
| FY2019 | 111.8M | +11% |
| FY2018 | 101.1M | +5% |
| FY2017 | 96.1M | +12% |
| FY2016 | 85.8M | +1% |
| FY2015 | 84.9M | +10% |
| FY2014 | 77M | +22% |
| FY2013 | 62.9M | +21% |
| FY2012 | 51.8M | +22% |
| FY2011 | 42.5M | +1% |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 138.3M | +6% | |
| Q1 FY26 | 138.2M | +7% | |
| Q4 FY25 | 136.3M | +6% | |
| Q3 FY25 | 137.3M | +7% | |
| Q2 FY25 | 130.6M | +3% | |
| Q1 FY25 | 129.7M | +3% | |
| Q4 FY24 | 129.1M | +3% | |
| Q3 FY24 | 128.6M | −2% | |
| Q2 FY24 | 126.7M | +2% | |
| Q1 FY24 | 126.1M | +2% | |
| Q4 FY23 | 125.6M | +2% | |
| Q3 FY23 | 131.3M | +8% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Alnylam Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.